Japan-based researchers have developed a test that will help pinpoint the chronic myeloid leukemia patients who could show resistance to imatinib, the standard treatment for blood cancer. "With our test, we can identify the most suitable drug, dose and/or drug combination, enabling therapy to be tailor-made for each individual patient," a researcher said.

Full Story:

Related Summaries